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Abstract
AIM: To clarify the role of surgical resection for mul-
tiple hepatocellular carcinomas (HCCs) compared to 
transarterial chemoembolization (TACE) and liver trans-
plantation (LT).
METHODS: Among the HCC patients who were man-
aged at Yonsei University Health System between Janu-
ary 2003 and December 2008, 160 patients who met 
the following criteria were retrospectively enrolled: (1) 
two or three radiologically diagnosed HCCs; (2) no ra-
diologic vascular invasion; (3) Child-Pugh class A; (4) 
main tumor smaller than 5 cm in diameter; and (5) 
platelet count greater than 50 000/mm3. Long-term 
outcomes were compared among the following three 
treatment modalities: surgical resection or combined ra-
diofrequency ablation (RFA) (n  = 36), TACE (n  = 107), 
and LT (n  = 17). The survival curves were computed 
using the Kaplan-Meier method and compared with 
a log-rank test. To identify the patients who gained a 
survival benefit from surgical resection, we also inves-
tigated prognostic factors for survival following surgical 
resection. Multivariate analyses of the prognostic fac-
tors for survival were performed using the Cox propor-
tional hazard model.
RESULTS: The overall survival (OS) rate was signifi-
cantly higher in the surgical resection group than in the 
TACE group (48.1% vs  28.9% at 5 years, P  < 0.005). 
LT had the best OS rate, which was better than that of 
the surgical resection group, although the difference 
was not statistically significant (80.2% vs  48.1% at 5 
years, P  = 0.447). The disease-free survival rates were 
also significantly higher in the LT group than in the 
surgical resection group (88.2% vs  11.2% at 5 years, 
P  < 0.001). Liver cirrhosis was the only significant 
prognostic factor for poor OS after surgical resection. 
Clinical liver cirrhosis rates were 55.6% (20/36) in the 
resection group and 93.5% (100/107) in the TACE 
group. There were 19 major and 17 minor resections. 
En bloc  resection was performed in 23 patients, multi-
site resection was performed in 5 patients, and com-
bined resection with RFA was performed in 8 patients. 
In the TACE group, only 34 patients (31.8%) were 
recorded as having complete remission after primary 
TACE. Seventy-two patients (67.3%) were retreated 
with repeated TACE combined with other therapies. 
In patients who underwent surgical resection, the 16 
patients who did not have cirrhosis had higher 5-year 
OS and disease-free survival rates than the 20 patients 
who had cirrhosis (80.8% vs  25.5% 5-year OS rate, 
P  = 0.006; 22.2% vs  0% 5-year disease-free survival 
rate, P  = 0.048). Surgical resection in the 20 patients 
who had cirrhosis did not provide any survival benefit 
when compared with TACE (25.5% vs  24.7% 5-year 
OS rate, P  = 0.225). Twenty-nine of the 36 patients 
who underwent surgical resection experienced recur-
rence. Of the patients with cirrhosis, 80% (16/20) 
were within the Milan criteria at the time of recurrence 
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after resection.
CONCLUSION: Among patients with two or three HCCs, 
no radiologic vascular invasion, and tumor diameters ≤ 
5 cm, surgical resection is recommended only in those 
without cirrhosis.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
Surgical resection is the established treatment modality 
for hepatocellular carcinoma (HCC) in patients with pre-
served liver function, and surgical outcomes have been 
greatly improved with mortality rates of  0%-6.4% and 
excellent 5-year survival rates of  more than 50%[1-3]. 
However, for patients with multiple HCCs, unfavorable 
disease-free and overall survival (OS) rates following sur-
gical resection have led to the contraindication of  surgi-
cal treatment. This contraindication is reflected in the 
guidelines suggested by the American Association for 
the Study of  Liver Disease[4] and the European Associa-
tion for the Study of  the Liver[5] based on the Barcelona 
Clinic Liver Cancer (BCLC) staging system. Thus, liver 
transplantation is recommended as the best option for 
patients with multiple HCCs, but a worldwide shortage 
of  donor organs greatly limits the application of  this 
recommendation. Therefore, although multidisciplinary 
strategies are used in the treatment of  multiple HCCs, 
multiple HCCs still pose a therapeutic challenge and are 
a matter of  debate. 
Currently, the main treatment modality for multiple 
HCCs is transarterial chemoembolization (TACE). Al-
though several expert centers have recently reported en-
couraging durable long-term outcomes of  surgical resec-
tion for multiple HCCs (50%-60% at 5 years) in patients 
with well-preserved liver function[6,7], few comparative 
studies of  surgical resection and liver transplantation (LT).
ACE have been reported[8,9]. Therefore, we designed 
this study to clarify the role of  surgery for multiple HCCs 
by comparing the long-term outcomes following surgical 
resection, TACE, and LT and investigating prognostic 
factors in patients who underwent surgical resection.
MATERIALS AND METHODS
Patient evaluation and follow-up
We analyzed a single-institution database of  3928 pa-
tients who received their initial treatments for HCCs at 
Yonsei University Health System, Seoul, South Korea 
between January 2003 and December 2008. The In-
stitutional Review Board of  Yonsei University Health 
System approved this study. Of  the patients who under-
went surgical resection (n = 304), TACE (n = 854), and 
LT (n = 45), the patients who met the following criteria 
were enrolled in this retrospective, single-cohort study: 
(1) two or three radiologically diagnosed HCCs; (2) no 
radiologic vascular invasion; (3) Child-Pugh class A; (4) 
main tumor smaller than 5 cm in diameter; and (5) a 
platelet count greater than 50 000/mm3. Small satellite 
nodules found in the resected specimen were not in-
cluded in this study. 
The cutoff  value of  tumor size for therapeutic deci-
sion making is a debated issue. The 7th edition of  can-
cer staging of  the American Joint Committee on Cancer 
describes main tumor size greater than 5 cm in multiple 
tumors as an independent prognostic factor for sur-
vival[10]. Additionally, a study comparing the pathologi-
cally proven necrosis rate following TACE reported the 
following frequencies of  complete necrosis according 
to tumor size: 66.7%, 30% and 0% for ≤ 3.0 cm, 3.1-5.0 
cm, and > 5.0 cm, respectively[11]. Although TACE has 
been performed as palliative care for larger HCCs, the 
OS rates of  patients with tumors larger than 5 cm in 
diameter are very poor[12,13]. In addition to tumor size, 
the presence of  vascular involvement of  the tumor is 
a significant prognostic factor for poor outcome. The 
5-year survival rates among patients with tumors with 
and without macroscopic vascular invasion are signifi-
cantly different (48% ± 3% vs 14% ± 5%, P < 0.001)[14]. 
Therefore, patients with a tumor ≥ 5 cm in diameter or 
with macroscopic vascular involvement were excluded 
from this study because those patients were unsuitable 
for curative therapy. 
Ultimately, we included 36 patients who underwent 
surgical resection or combined resection with radio-
frequency ablation (RFA), 107 patients who received 
TACE, and 17 patients who underwent LT, and we 
compared long-term outcomes following the respective 
treatments.
 Patients were evaluated preoperatively by abdominal 
ultrasonography (US), computed tomography (CT), mag-
netic resonance imaging (MRI), and hepatic angiography, 
if  indicated. All patients were assessed using alpha-feto-
protein (AFP), protein induced by vitamin K absence or 
antagonist Ⅱ (PIVKA Ⅱ), hepatitis B surface antigen, 
anti-hepatitis C viral antibody, liver biochemistry, coagu-
lation test, and indocyanine green retention rate at 15 
min (ICG R15). 
 The selection of  therapeutic options was determined 
by the anatomical locations of  the tumors, liver function-
al reserve, and patient preference. TACE was generally 
considered when the tumor was ineligible for complete 
surgical removal, low remnant liver volume was expected 
after resection, or the patients declined operative inter-
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vention. The patients who had an available liver donor 
underwent LT.
Eradicating all of  the multifocal tumors required a 
multimodality approach using not only en-bloc resection 
but also separate multi-site resection or resection com-
bined with RFA. All of  the patients who underwent sur-
gical resection were routinely assessed by intra-operative 
US. The effectiveness and safety of  combined hepa-
tectomy with RFA for multi-site HCCs were reported 
by Choi et al[15], and our previous work has also shown 
comparable results between en-bloc resection and multi-
site resection or combination hepatectomy with RFA[16]. 
Separate multi-site resection or resection plus RFA was 
performed for the multifocal tumors ineligible for en-
bloc resection because of  bilobar involvement or when 
there was not enough hepatic function reserve after en-
bloc resection. Wedge resection was considered for super-
ficial tumors, and RFA was performed for tumors less 
than 3 cm in diameter that were located deep in the liver. 
The median follow-up period for the patients who 
underwent surgical resection was 38.6 mo (range: 1-94 
mo). Surveillance after treatment was conducted with 
regular monitoring of  AFP, PIVKA Ⅱ, and US or CT 
every three to six months. Suspicious intrahepatic recur-
rence was confirmed by MRI, hepatic angiography, or 
image-guided fine-needle biopsy, if  needed.
To identify the patients who gained a survival benefit 
from surgical resection, we also investigated prognostic 
factors for survival following surgical resection. Twelve 
clinical variables recorded at the time of  diagnosis were 
analyzed. The variables included age at diagnosis; sex; se-
rum albumin; alanine aminotransferase (ALT) and aspar-
tate aminotransferase levels; ICG R15; serum AFP level; 
clinical liver cirrhosis; main tumor size and number of  
tumors on preoperative image studies; lobar distribution 
of  the tumor; and type of  operation.
Clinically diagnosed liver cirrhosis was defined as 
follows: (1) history of  overt complications of  liver cir-
rhosis, such as ascites, variceal bleeding, and hepatic 
encephalopathy; (2) evidence of  clinical portal hyperten-
sion, including esophageal or gastric varices, or spleno-
megaly (maximal diameter > 12 cm) with platelet count 
< 100 000 mm3; and (3) liver morphology suggesting 
the presence of  cirrhosis on preoperative image studies, 
including hypertrophy of  the left lobe and/or caudate 
lobe, relative volume reduction of  the right lobe, nodu-
larity of  the liver surface, presence of  regenerative or 
dysplastic nodules, or the presence of  a portosystemic 
shunt[17-19]. All of  the analysis in the current study were 
performed using a clinical diagnosis of  liver cirrhosis to 
evaluate its clinical usefulness. Minor resection was de-
fined as hepatectomy of  two or fewer liver segments.
Statistical analysis
Continuous variables are presented as the mean ± SD 
and were compared by Student’s t test. Categorical vari-
ables are expressed as frequencies with percentages and 
were compared by the χ 2 test. Cumulative overall and 
disease-free survival rates were computed by the Kaplan-
Meier method, and differences between the survival 
curves were compared using a log-rank test. Multivariate 
analyses of  the prognostic factors for survival were per-
formed using the Cox proportional hazard model and 
included the factors that had P values less than 0.1 upon 
univariate analysis. Statistical analyses were performed 
using SPSS 15 for Windows (SPSS Inc., Chicago, IL, 
United States). Statistical significance was set at a P value 
less than 0.05.
RESULTS
Clinical characteristics of the surgical resection group 
and TACE group 
The patients who underwent TACE were older and had 
lower platelet counts, higher ALT levels, and a higher 
rate of  clinical liver cirrhosis than those in the resection 
group. Clinical liver cirrhosis rates were 55.6% (20/36) in 
the resection group and 93.5% (100/107) in the TACE 
group. Surgical resection was performed more frequently 
in patients with larger diameter tumors (Table 1).
Operative procedures in the surgical resection group 
and additional treatments in the TACE group
Table 2 lists the operative procedures and combined treat-
ments with RFA in the resection group. There were 19 
and 17 major and minor resections, respectively. En bloc 
resection was performed in 23 patients, multi-site resec-
tion was performed in 5 patients, and combined resec-
tion with RFA was performed in 8 patients. In the TACE 
group, only 34 patients (31.8%) were recorded as having 
complete remission after primary TACE. Seventy-two 
patients (67.3%) were retreated with repeated TACE, 
one patient was retreated with repeated TACE and intra-
arterial chemotherapy, two patients were retreated with 
RFA, two patients were retreated with radiation therapy, 
one patient was retreated with percutaneous ethanol 
injection, two patients were retreated with intra-arterial 
chemotherapy and systemic chemotherapy, two patients 
were retreated with intra-arterial chemotherapy and ra-
diation therapy, and five patients were retreated with hol-
mium therapy.
Long-term outcomes according to treatment modality
The OS rate was significantly higher in the surgical re-
section group than in the TACE group (48.1% vs 28.9% 
at 5 years, P < 0.005) (Figure 1A). LT had the best OS 
rate, which was better than that of  the surgical resec-
tion group, although the difference was not statistically 
significant (80.2% vs 48.1% at 5 years, P = 0.447) (Figure 
1A). The disease-free survival rates were also significantly 
higher in the LT group than in the surgical resection 
group (88.2% vs 11.2% at 5 years, P < 0.001) (Figure 1B).
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Table 1  Clinical characteristics of the surgical resection 
patients vs  the transarterial chemoembolization patients
Variable Surgical resection 
(n  = 36)
TACE 
(n  = 107)
P  value
Age (yr)         54.3 ± 8.6        61.2 ± 9.3 < 0.001
Gender (male:female) 34:2 86:21    0.047
Platelet (k/mm3)       153.4 ± 53.9      121.0 ± 51.8    0.002
Albumin (g/dL) 4.05 ± 0.50 3.93 ± 0.48    0.203
ALT (IU/L) 36.4 ± 15.8 59.0 ± 40.4    0.001
AST (IU/L) 41.2 ± 25.8 53.2 ± 44.7    0.130
HBsAg 28 (77.8) 67 (62.6)    0.099
Clinical liver cirrhosis 20 (55.6)        100 (93.5) < 0.001
Tumor number    0.549
   2 30 (83.3) 90 (84.1)
   3   6 (16.7) 17 (15.9)
Main tumor size (cm)    0.005
   < 3 19 (52.8) 17 (47.2)
   ≥ 3 29 (27.1) 78 (72.9)
AFP > 1000 IU/mL 2 (5.6) 8 (7.5)    0.696
Data are expressed as absolute n (%) or mean ± SD. M: Male; F: Female; 
TACE: Transarterial chemoembolization; ALT: Alanine aminotransferase 
(reference range, 5-46 IU/L); AST: Aspartate aminotransferase (reference 
range, 13-34 IU/L); HBsAg: Hepatitis B surface antigen; AFP: α-fetoprotein.
Degree of resection Operative procedure Number of 
patients (n  = 36)
Major resection Extended right hepatectomy 1
(n = 19) Right hepatectomy only              12
+ wedge resection 1
+ RFA 1
Left hepatectomy only 1
+ wedge resection 1
Central bisectionectomy only 2
Minor resection Left lateral sectionectomy only 3
(n = 17) + RFA 1
Sectionectomy only 2
+ wedge resection 2
+ RFA 2
Bisegmentectomy only 1
+ wedge resection 1
+ RFA 2
Segmentectomy only 1
+ RFA 1
Wedge resection + RFA 1
Figure 1  The overall and disease-free survival curves according to treatment modality and presence of liver cirrhosis in surgical resection patients. A: The 1-, 
3- and 5-year overall survival (OS) rates were 94.1%, 80.2% and 80.2%, respectively, in the liver transplantation (LT) group; 91.7%, 83.3% and 48.1%, respectively, in 
the resection group; and 88.7%, 55.6% and 28.9%, respectively, in the transarterial chemoembolization (TACE) group. The OS rate was significantly higher in the surgi-
cal resection group than in the TACE group (P < 0.005). LT showed the best OS rate (better than the surgical resection group, but not statistically significant, P = 0.447); 
B: The 1-, 3- and 5-year disease-free survival rates were 88.2%, 88.2% and 88.2% in the LT group and 60%, 30.3% and 11.2% in the resection group, respectively. The 
disease-free survival rates were also significantly higher in the transplantation group than in the surgical resection group (P < 0.001); C: The 1-, 3- and 5-year OS rates 
were 100%, 100% and 80.8% in patients without cirrhosis (-) and 87.5%, 75% and 25.5% in patients with cirrhosis (+), respectively (P = 0.006); D: The 1-, 3- and 5-year 
disease-free survival rates were 75.0%, 50.0% and 22.2% in patients without cirrhosis (-) and 52.3%, 18.7% and 0% in patients with cirrhosis (+), respectively (P = 0.048).
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Prognostic factors for OS in patients who underwent 
surgical resection
Cirrhosis was the only significant prognostic factor for 
poor OS after resection in both the univariate (P = 0.023) 
and multivariate analyses (P = 0.034, odds ratio = 0.552, 
95%CI: 0.105-0.915) (Table 3). Clinically diagnosed liver 
cirrhosis was correlated with pathological cirrhosis with 
a positive predictive value of  100%, a negative predictive 
value of  75%, a sensitivity of  83.3%, and a specificity of  
100%.
Long-term outcomes of patients who underwent surgical 
resection according to the presence of cirrhosis 
The 1-, 3- and 5-year OS rates were 100%, 100% and 
80.8%, respectively, in 16 patients without cirrhosis, and 
87.5%, 75% and 25.5%, respectively, in 20 patients with 
cirrhosis (P = 0.006) (Figure 1C). The disease-free 1-, 3- 
and 5-year survival rates were 75.0%, 50% and 22.2%, re-
spectively, in patients without cirrhosis and 52.3%, 24.9% 
and 0%, respectively, in patients with cirrhosis (P = 0.048) 
(Figure 1D). The OS rates were not different between 
the surgical resection group and the TACE group among 
the patients with cirrhosis (87.5%, 75.0% and 25.5% vs 
91.8%, 61.7% and 24.7% at 1-, 3- and 5-year, respectively, 
P = 0.225) (Figure 2). 
Recurrence pattern after surgical resection
Twenty-nine of  the 36 patients who underwent surgical 
resection experienced recurrence. Of  the 29 patients with 
recurrence, 1 (4%) had a marginal recurrence on the resec-
tion margin, 21 (84%) had intra-hepatic recurrences, and 3 
(12%) had extra-hepatic recurrences with one in the lung 
and two in bone. All of  the patients with marginal and 
intra-hepatic recurrence were retreated by TACE. Chemo-
therapy, radiation therapy, and a clinical trial were used to 
treat extra-hepatic recurrences. Notably, of  the patients 
with cirrhosis, 80% (16/20) were within the Milan criteria 
at the time of  recurrence after resection.
DISCUSSION
Our study demonstrates that surgery for patients with 
multiple HCCs is recommended in patients without cir-
rhosis. Our data revealed that the survival of  patients 
who underwent surgical resection was better than that 
of  patients who received TACE. However, the survival 
of  patients with HCCs was affected not only by HCC 
itself, but also by underlying liver disease. The majority 
of  patients (93.5%, 100/107) who received TACE had 
liver cirrhosis. Therefore, when the survival of  the pa-
tients in the surgical resection group was compared with 
the TACE group according to the presence of  cirrhosis, 
surgical resection showed no survival benefit in cirrhotic 
patients.
To confirm the efficacy of  surgical resection for mul-
Table 3  Prognostic factors for overall survival in surgical re-
section patients
Variable Patients 
(n  = 36)
1-yr OS 3-yr OS 5-yr OS P  
value
Age (yr) 0.146
   ≤ 60 27 88.9% 81.5% 42.3%
   > 60   9  100% 88.9% 66.7%
Gender 0.245
   Male 34 91.2% 82.4% 45.1%
   Female   2  100%  100%  100%
Serum albumin (g/dL) 0.642
   ≤ 3.5 10 90.0% 60.0% 48.0%
   > 3.5 26 92.3% 87.7% 46.1%
ALT (IU/L) 0.593
   ≤ 50 27 92.6% 81.5% 53.7%
   > 50   9 88.9% 71.1% 23.7%
AST (IU/L) 0.87
   ≤ 50 31 90.3% 80.6% 52.4%
   > 50   5  100%  100% 50.0%
ICG R 15 (%) 0.992
   ≤ 14 25 92.0% 84.0% 47.1%
   > 14   9 88.9% 77.8% 58.3%
α-fetoprotein 0.471
   ≤ 1000 IU/mL 32 90.6% 81.3% 47.3%
   > 1000 IU/mL   4  100%  100% 50.0%
Cirrhosis 0.023
   No 16  100% 93.8% 69.9%
   Yes 20 85.0% 75.0% 26.5%
Main tumor size (cm) 0.629
   < 3.0 17 94.1% 86.3% 43.1%
   ≥ 3.0 19 89.5% 73.7% 52.6%
Number of tumors 0.061
   2 31 90.3% 80.6% 40.7%
   3   5  100%  100%  100%
Lobar distribution of tumors 0.892
   One lobes 24 91.7% 83.3% 49.4%
   Two lobe 12 91.7% 83.3% 48.6%
Operation type 0.568
   En bloc resection 23 91.3% 82.6% 43.4%
   Multiple resection or 
   combined with RFA
13 92.3% 84.6% 57.1%
OS: Overall survival; RFA: Radiofrequency ablation; ALT: Alanine ami-
notransferase; AST: Aspartate aminotransferase; ICG R 15: Indocyanine 
green retention rate at 15.
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Figure 2  Overall survival curves of surgical resection and transarterial 
chemoembolization in patients with liver cirrhosis. Among patients with cir-
rhosis, the overall survival (OS) rates were not different between the surgical 
resection group and the transarterial chemoembolization (TACE) group (25.5% 
vs 24.7% 5-year OS rate, P = 0.225).
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tiple HCCs, its superiority over non-surgical treatment 
(TACE) should be proven. A recent retrospective cohort 
study by Ho et al[8] reported that hepatectomy yields bet-
ter survival than TACE even in patients with multiple 
HCCs in various stages. The authors compared the 
prognosis of  the patients according to stages in differ-
ent staging systems; however, as the authors note, their 
study had several weaknesses. Although each staging 
system represents the prognosis of  the patients who 
have HCC, and in particular, the BCLC system accounts 
for portal hypertension and the bilirubin level in addi-
tion to the Child-Pugh classification in staging, the liver 
function status in each stage encompasses a wide range 
and the prognosis in the subgroups of  each stage differs 
significantly[20]. Additionally, the patients in each stage 
of  their study were heterogeneous. Therefore, it is un-
clear whether the degree of  underlying liver disease was 
evenly distributed between the compared groups. In our 
study, we limited the inclusion criteria to patients with 
platelet counts greater than 50 000/mm3 in addition to a 
Child-Pugh A classification to exclude patients who had 
severely advanced liver cirrhosis, for whom surgery is 
contraindicated due to likely postoperative deterioration 
of  liver function and poor prognosis[17,21]. 
Liver cirrhosis is a well-known potent predictive fac-
tor for OS in patients with HCC[14,22,23], as shown in our 
patient cohort. According to our analysis, the survival rates 
of  cirrhotic patients with multiple HCCs who underwent 
surgical resection were extremely disappointing. The 5-year 
OS rate of  the patients with cirrhosis was 25.5%, which 
was significantly worse than that of  the patients without 
cirrhosis (69.3%, P = 0.006) (Figure 1C and D). Further-
more, the outcomes of  surgical resection and TACE in 
the patients with cirrhosis were not different (Figure 2). 
Therefore, surgical resection for multiple HCCs would be 
beneficial in patients without cirrhosis, but it remains de-
batable in patients with cirrhosis.
Despite the fact that surgical resection for multiple 
HCCs showed acceptable OS rates in our study as well 
as in several other publications[6-8,22,24], a high recurrence 
rate is a major drawback of  surgical resection as a cura-
tive therapy. According to our data, the 5-year disease-
free survival rates were 0% in patients with cirrhosis 
and 22.2% in non-cirrhotic patients. Thus, our single 
cohort study demonstrated that LT might be the pre-
ferred treatment option to offer the chance of  a cure for 
multiple HCCs; the OS and disease-free survival rates 
were 80.2% and 88.2%, respectively (Figure 1A and B). 
However, in addition to inevitable immuneesuppressive 
therapy, which has an adverse oncologic effect, the scar-
city of  liver donors is another great obstacle to the wide 
application of  LT.
Which loco-regional therapy is superior as a bridge 
to LT is an issue because of  the long waiting time on the 
transplant list, which results in patients progressing and 
falling outside the transplant criteria. According to Ll-
ovet et al[25], approximately 10% of  patients are dropped 
from the transplant list during the waiting period because 
of  tumor progression or liver failure. TACE and RFA 
have been studied in detail and widely used as a bridge 
therapy in several transplant centers, but the efficacy of  
these modalities has not yet been established[26-28]. 
Recently, Belghiti et al[29] proposed three different roles 
of  resection for HCC prior to LT: (1) As a primary ther-
apy, resection can delay or avoid transplantation and can 
be followed by salvage transplantation for recurrence and 
deteriorated liver function; (2) As an initial therapy, resec-
tion can provide pathologic information about the whole 
specimen, which enables selection of  the best candidates 
for transplantation; and (3) As a bridge therapy, resection 
can offer the best control of  HCC in patients listed for 
LT through the possibility of  downstaging and provid-
ing detailed pathologic information. In addition to these 
benefits, liver resection can provide superior control and 
a good survival rate[29,30]. Furthermore, several studies re-
port that 60%-80% of  patients who recur after resection 
for HCC are still amenable to transplantation, and these 
results are not different between patients with solitary 
and oligonodular primary HCCs[22,31,32]. Our results also 
showed that 80% of  the recurred patients with cirrhosis 
following resection were within the Milan criteria. Thus, 
surgical resection for cirrhotic patients with multiple 
HCCs might be performed as a bridge to LT. Surgical 
resection as a bridge is justified by the improved safety of  
liver surgery and no survival impairment in the event of  
subsequent LT[31]. 
Recent studies demonstrated that salvage LT does not 
compromise the operative morbidity and mortality com-
pared with primary LT[31,33,34]. In contrast, Adam et al[35] 
reported that secondary LT is associated with a higher 
operative morbidity and mortality; they also argued that 
patients treated by resection when they were initially 
transplantable had a higher recurrence rate with more 
frequent extrahepatic metastasis and vascular invasion, 
which impair the transplantability and long-term survival 
of  the patients. Therefore, it is too early to conclude 
whether resection can be performed as bridge therapy. 
Nevertheless, these efforts to use the limited number of  
donor organs effectively are necessary, as is further inves-
tigation of  this issue.
We did not analyze the outcomes according to the 
types of  multiple HCCs in the present study because our 
data included patients who received resection combined 
with RFA, which did not allow for pathologic analysis. 
Discrimination of  intrahepatic metastasis (IM) and de 
novo multicentric (MC) HCCs may be important because 
generally, IMs that have acquired metastatic ability ex-
hibit more aggressive biologic behavior[36,37] and thus in-
fluence therapeutic strategy decisions. According to the 
guidelines of  the Liver Cancer Study Group of  Japan[38], 
IM is diagnosed if  the tumors definitely originated from 
portal vein tumor thrombi, if  the tumors arose in mul-
tiple satellite nodules surrounding a main tumor, or if  
a satellite tumor near the main tumor shows similar or 
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poorer histological differentiation than the main tumor. 
Otherwise, multiple HCCs that do not meet these con-
ditions are deemed de novo MC tumors. Although these 
conventional pathological criteria are convenient, they 
are relatively subjective. Currently, the most precise 
method to determine the origin of  HCC is DNA clonal 
analysis[39,40], and clinical differentiation between IM and 
MC is not possible preoperatively. If  a credible diagnosis 
could be possible for preoperative distinction of  the ori-
gin of  multiple nodules, it might be helpful for the selec-
tion of  therapy. 
In conclusion, surgical resection for HCCs with two 
or three radiologically identified tumors, no radiologic 
vascular invasion, and diameters less than 5 cm is rec-
ommended for patients without cirrhosis but debat-
able for patients with cirrhosis. LT might be the best 
treatment option for patients with multiple HCCs. The 
retrospective design and the small number of  cases 
are limitations of  this-single cohort study. Therefore, 
further multi-center trials and randomized, controlled, 
prospective studies are needed, especially to examine 
the role of  surgical resection in cirrhotic patients with 
multiple HCCs. 
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